Biomarkers as drug development tools: discovery, validation, qualification and use
暂无分享,去创建一个
[1] M. Karsdal,et al. Serum Markers of Liver Fibrosis: Combining the BIPED Classification and the Neo-Epitope Approach in the Development of New Biomarkers , 2010, Disease markers.
[2] E. Ziv,et al. The Importance of Biopsy in the Era of Molecular Medicine , 2016, Cancer journal.
[3] D. Galasko,et al. A cerebrospinal fluid microRNA signature as biomarker for glioblastoma , 2017, Oncotarget.
[4] S. Teutsch,et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group , 2009, Genetics in Medicine.
[5] C. Kwoh,et al. Prediction of medial tibiofemoral compartment joint space loss progression using volumetric cartilage measurements: Data from the FNIH OA biomarkers consortium , 2017, European Radiology.
[6] H. Portugal,et al. Stability study of 81 analytes in human whole blood, in serum and in plasma. , 2012, Clinical biochemistry.
[7] D. DeMets,et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.
[8] M. Nevitt,et al. Predictive validity of biochemical biomarkers in knee osteoarthritis: data from the FNIH OA Biomarkers Consortium , 2016, Annals of the rheumatic diseases.
[9] M. Karsdal,et al. Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. , 2015, Osteoarthritis and cartilage.
[10] Federico M Goodsaid,et al. Strategic paths for biomarker qualification. , 2008, Toxicology.
[11] J. James,et al. Biomarkers in connective tissue diseases , 2017, The Journal of allergy and clinical immunology.
[12] D. Burstein,et al. A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials. , 2010, Current drug targets.
[13] M. Mattson,et al. Age-Related Changes in Plasma Extracellular Vesicle Characteristics and Internalization by Leukocytes , 2017, Scientific Reports.
[14] A R Poole,et al. Application of Biomarkers in the Development of Drugs Intended for the Treatment of Osteoarthritis OARSI FDA Osteoarthritis Biomarkers Working Group , 2011 .
[15] S. Amur,et al. Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization , 2015, Clinical pharmacology and therapeutics.
[16] R. Altman,et al. Celecoxib pathways: pharmacokinetics and pharmacodynamics. , 2012, Pharmacogenetics and genomics.
[17] D. Swinney. The value of translational biomarkers to phenotypic assays , 2014, Front. Pharmacol..
[18] Jerry Avorn,et al. New "21st Century Cures" Legislation: Speed and Ease vs Science. , 2017, JAMA.
[19] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[20] M. Karsdal,et al. Molecular Serum Markers of Liver Fibrosis , 2012, Biomarker insights.
[21] F. Cicuttini,et al. Measuring Disease Progression in Osteoarthritis , 2016, Current Treatment Options in Rheumatology.
[22] Dieter Deforce,et al. The European Medicines Agency experience with biomarker qualification. , 2015, Methods in molecular biology.
[23] J. Wagner,et al. Biomarkers and Surrogate End Points for Fit‐for‐Purpose Development and Regulatory Evaluation of New Drugs , 2007, Clinical pharmacology and therapeutics.
[24] D J Hunter,et al. Classification of osteoarthritis biomarkers: a proposed approach. , 2006, Osteoarthritis and cartilage.
[25] D. A. van der Windt,et al. Generic prognostic factors for musculoskeletal pain in primary care: a systematic review , 2017, BMJ Open.
[26] W. Lems,et al. Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. , 2010, Osteoarthritis and cartilage.
[27] F. Blanco. Osteoarthritis year in review 2014: we need more biochemical biomarkers in qualification phase. , 2014, Osteoarthritis and cartilage.
[28] D J Greenblatt,et al. Pharmacokinetics and pharmacodynamics. , 1990, Hospital practice.
[29] E. Israel,et al. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. , 2011, The New England journal of medicine.
[30] G. Stein,et al. Viral Load as a Surrogate End Point in HIV Disease , 2002, The Annals of pharmacotherapy.
[31] W. Weaver,et al. Molecular biology: origin of the term. , 1970, Science.
[32] Erin E Kepplinger,et al. FDA's Expedited Approval Mechanisms for New Drug Products. , 2015, Biotechnology law report.
[33] E. Losina,et al. OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis. , 2015, Osteoarthritis and cartilage.